Does Highmark Cover Ozempic?
The verdict
Conditional on most plans
Highmark covers Ozempic for type 2 diabetes with prior authorization. Ozempic follows Highmark's standard T2D prior-authorization pathway — not the restrictive J-0184 anti-obesity policy or J-1370 cardiovascular incentive policy that govern Wegovy. Tier varies (preferred or non-preferred brand) across Highmark's western Pennsylvania, Delaware, and West Virginia plans. Off-label weight-loss use is not covered.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Highmark using your member ID.
Key facts
Highmark's J-0184 anti-obesity PA policy (lifestyle program, BMI criteria, 5% weight-loss renewal) applies to Wegovy — not to Ozempic for T2D, which uses a separate, simpler standard diabetes PA pathway.
Highmark Medical Policy J-0184 (Anti-Obesity Medications)
Ozempic is FDA-approved for type 2 diabetes glycemic control, cardiovascular risk reduction in T2D patients with known CVD, and CKD progression in T2D patients — not for weight loss.
FDA drug labeling (semaglutide injection)
The IRA Maximum Fair Price for semaglutide under Medicare is $274 per 30-day supply, effective January 1, 2027 — a 71% discount off the CY2024 list price.
CMS, IRA Drug Price Negotiation Program, 2024
Medicare vs. commercial coverage
Whether Highmark covers Ozempic depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Advantage (Highmark Wholecare and affiliated plans): Ozempic is covered for type 2 diabetes with prior authorization under standard Part D rules. PA requires a T2D diagnosis and oral agent step therapy. The 2026 Part D out-of-pocket cap is $2,100. Medicare beneficiaries cannot use the NovoCare savings card. The IRA Maximum Fair Price for semaglutide drops to $274 per 30-day supply effective January 1, 2027. Note: Highmark's J-1370 cardiovascular incentive policy governs Wegovy for the CV indication at Highmark Medicare; this is a separate policy from the standard T2D PA pathway for Ozempic and does not apply to Ozempic. Ozempic is not covered for off-label weight-loss use under any Highmark Medicare plan.
Commercial / Employer
Group & marketplace plans
Commercial/Employer: Highmark operates in western Pennsylvania, Delaware, and West Virginia. Ozempic is covered for type 2 diabetes with prior authorization and oral agent step therapy. Tier varies — preferred or non-preferred brand across Highmark's commercial plan designs; verify on the Highmark drug lookup tool. Not covered for off-label weight-loss use. Commercially insured T2D patients may be eligible for the NovoCare Ozempic Savings Card ($25/fill, max $150/28-day) — verify at NovoCare.com. ACA/Individual: covered for T2D with PA; weight-loss use excluded. Medicaid (Highmark Medicaid/Gateway Health): covered for T2D with PA at nominal cost-share. Not covered for weight loss. Important distinction: Highmark's J-0184 anti-obesity policy (lifestyle program requirements, BMI criteria, 5% weight-loss renewal) applies to Wegovy and anti-obesity agents — it does not govern Ozempic for T2D. These are two completely separate PA pathways.
The 3 boxes you must tick to get approved
Commercial plans that will consider Ozempic require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Ozempic actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
~$1,028/month (Novo Nordisk published pricing, ~$1,027.51 for the 0.25/0.5 mg pen). NovoCare self-pay: ~$199/month intro price (first two fills through December 31, 2026), then ~$349/month (0.25/0.5/1 mg) or ~$499/month (2 mg).
List price with no coverage — before any manufacturer savings card.
With coverage
Commercial: tier-based cost-share; preferred or non-preferred brand depending on Highmark plan — verify on Highmark drug lookup. Medicare Advantage: tier-based cost-share; $2,100 Part D OOP cap 2026; IRA Maximum Fair Price of $274/30-day effective January 1, 2027. Medicaid: $0–$4 nominal cost-share for T2D use.
Typical monthly copay once prior authorization is approved.
Bridge program
NovoCare Ozempic Savings Card: commercially insured T2D patients may pay as little as $25 per fill (max $150/28-day). Not available to Medicare or Medicaid beneficiaries. Verify at NovoCare.com.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Tier and cost-share vary across Highmark's PA, Delaware, and WV plans. Confirm exact cost-share on the Highmark drug lookup tool or by calling Highmark member services.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Use the Highmark drug lookup to confirm tier and PA requirements
Log in at highmark.com and use the drug lookup tool to confirm Ozempic tier (preferred vs. non-preferred brand) and PA requirements under your specific Highmark commercial, Medicare Advantage, or Medicaid plan. Tier and criteria vary across Highmark's western Pennsylvania, Delaware, and West Virginia plan footprint.
- 2
Have your prescriber initiate standard T2D prior authorization
Highmark's T2D PA is much simpler than its Wegovy anti-obesity pathway (J-0184). The Ozempic PA requires: type 2 diabetes diagnosis (ICD-10 E11.x), documented metformin use or contraindication, and clinical framing as T2D management — not weight loss. Prepare these three elements and the PA submission is straightforward.
- 3
Note the IRA price drop for Medicare patients in 2027
If you are enrolled in Highmark Medicare Advantage, the IRA Maximum Fair Price for semaglutide drops to $274 per 30-day supply on January 1, 2027. In 2026, the $2,100 Part D OOP cap limits maximum annual exposure. Call Highmark member services for a personalized cost estimate.
Options if Highmark won't cover Ozempic
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Rybelsus (oral semaglutide)
Oral semaglutide for type 2 diabetes. Subject to the same T2D PA at Highmark. Also subject to IRA Maximum Fair Price of $274/30-day effective January 1, 2027 for Medicare patients. Verify tier on Highmark drug lookup.
Jardiance (empagliflozin)
SGLT-2 inhibitor commonly used as step therapy before GLP-1 approval. Often a preferred brand tier on Highmark formularies with lower cost-share than non-preferred Ozempic.
Metformin (generic)
Tier 1 on virtually all Highmark formularies at near-zero cost-share. Required step therapy before Ozempic PA on Highmark commercial and Medicaid plans.
Compounded semaglutide (weight-loss seekers only)
For patients seeking semaglutide for weight management — Highmark's Wegovy coverage requires the J-0184 anti-obesity pathway (lifestyle program, BMI criteria, 5% weight-loss renewal). For patients who want semaglutide without navigating Highmark's anti-obesity PA, compounded semaglutide from $49/mo is available at getcurex.com/cl/glp. See the offer section below.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
No. Highmark does not cover Ozempic for off-label weight-loss use under any plan. Ozempic is FDA-approved only for type 2 diabetes — not weight management. Highmark's J-0184 anti-obesity policy governs Wegovy coverage and requires lifestyle programs, BMI criteria, and weight-loss renewal milestones. Even that policy does not cover Ozempic for weight loss — it covers Wegovy for obesity. Ozempic for weight loss is off-label and denied across all Highmark lines of business.
Highmark's J-0184 anti-obesity policy applies to Wegovy and other anti-obesity agents, requiring documented lifestyle programs, BMI criteria, and ongoing ≥5% weight-loss maintenance for reauthorization. The Ozempic T2D PA pathway is completely separate and far simpler — it requires a T2D diagnosis and metformin step-therapy documentation, without lifestyle program requirements or weight-loss renewal milestones. A T2D patient seeking Ozempic through Highmark is navigating the standard diabetes pathway, not the complex anti-obesity protocol.
Ozempic's tier varies across Highmark's plans — it may be classified as preferred or non-preferred brand depending on your specific Highmark commercial, Medicare Advantage, or Medicaid plan. Preferred brand tier means lower cost-share than non-preferred. Use the Highmark drug lookup tool at highmark.com to confirm the tier under your specific plan, as tier designation is not uniform across Highmark's Pennsylvania, Delaware, and West Virginia footprint.
Ozempic's FDA-approved indications include cardiovascular risk reduction in adults with type 2 diabetes and known heart disease. Highmark's standard T2D PA covers Ozempic for its full set of FDA-approved T2D indications, including the CV indication — this is distinct from Highmark's J-1370 cardiovascular incentive policy, which governs Wegovy's CV indication only. Coverage for the Ozempic CV/T2D indication requires the standard T2D PA (T2D diagnosis, step therapy) rather than any separate cardiovascular protocol.
Yes, if you are enrolled in a Highmark commercial plan (not Medicare or Medicaid). The NovoCare Ozempic Savings Card offers commercially insured T2D patients as little as $25 per fill (max $150 per 28-day supply). Verify eligibility at NovoCare.com. Highmark Medicare Advantage and Medicaid enrollees cannot use the card due to federal anti-kickback rules.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Anthem Cover Adderall? 2026 Coverage Guide | Curex
Anthem covers Adderall through CarelonRx — generic preferred, brand non-preferred. Step therapy may apply on some plans. Verify your Anthem plan.
Read moreDoes Anthem Cover Contrave? 2026 Brand Coverage Guide | Curex
Anthem covers Contrave only if your plan has a weight-loss benefit. Many plans carve it out. CurAccess ~$99/mo is often the fastest path.
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreInsurance won't cover Ozempic for weight loss — here's a path that doesn't need it
Highmark's weight-loss GLP-1 coverage (Wegovy) requires the J-0184 anti-obesity protocol. Ozempic for off-label weight use is not covered under any Highmark policy. Patients seeking semaglutide for weight management can access compounded semaglutide from $49/mo at getcurex.com/cl/glp — no Highmark PA required. Compounded semaglutide is not the same medication as Ozempic or Wegovy. Compounded tirzepatide is also available from $149/mo. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Ozempic and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Highmark before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Ozempic and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.